The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer
Eur Urol
.
2019 Mar;75(3):e51-e52.
doi: 10.1016/j.eururo.2018.11.003.
Epub 2018 Nov 16.
Authors
Joe M O'Sullivan
1
,
Daniel Heinrich
2
,
Nicholas D James
3
,
Sten Nilsson
4
,
Piet Ost
5
,
Christopher C Parker
6
,
Bertrand Tombal
7
Affiliations
1
Centre for Cancer Research and Cell Biology, Queen's University, Belfast City Hospital, Belfast, UK. Electronic address: joe.osullivan@qub.ac.uk.
2
Akershus University Hospital, Lørenskog, Norway.
3
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4
Karolinska Hospital, Stockholm, Sweden.
5
Ghent University, Ghent, Belgium.
6
Institute of Cancer Research, Sutton, UK.
7
Université Catholique de Louvain, Louvain, Belgium.
PMID:
30454914
DOI:
10.1016/j.eururo.2018.11.003
No abstract available
Publication types
Letter